stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Return on equity
BeOne Medicines Ltd. - Sponsored ADR's return on equity over the twelve months to 30 September 2026 was 18.4%, up 10.9 percentage points from fiscal 2025 (7.46%). Over the past ten years it has ranged from −94.9% (fiscal 2016) to 73.8% (fiscal 2015); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 7.46% | 26.23 |
| FY2024 | −18.8% | 3.49 |
| FY2023 | −22.3% | 15.85 |
| FY2022 | −38.1% | (8.96) |
| FY2021 | −29.2% | 36.73 |
| FY2020 | −65.9% | 3.57 |
| FY2019 | −69.5% | (14.17) |
| FY2018 | −55.3% | (37.33) |
| FY2017 | −18.0% | 76.99 |
| FY2016 | −94.9% | (168.71) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR | 18.4% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| ARGX argenex SE compare | 0.00% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| RVMD Revolution Medicines, Inc. compare | −93.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement